Lamb Peter
SEC CIK 1387306 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| EXEL | EXELIXIS, INC. | EVP, CSO, Scientific Strategy | 431.0K | — | $6.08M | 25 | 2021-07-15 | 2022-12-15 |
Most active insiders at EXEL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Aftab Dana | EVP, Research, Development | — | $7.70M |
| 2 | Haley Patrick J. | EVP, Commercial | — | $7.60M |
| 3 | Smith Julie | Dir | — | $4.69M |
| 4 | WYSZOMIERSKI JACK L | Dir | — | $4.58M |
| 5 | Senner Christopher J. | EVP, CFO | — | $4.56M |
| 6 | PAPADOPOULOS STELIOS | Dir | — | $4.36M |
| 7 | POSTE GEORGE | Dir | — | $2.74M |
| 8 | Beckerle Mary C | Dir | — | $1.93M |
| 9 | Oliver Bob | Dir | — | $1.33M |
| 10 | Caligan Partners LP | Dir, See Remarks | $1.19M | — |
Lamb Peter made no open-market trades at EXEL in the last 12 months.
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-16 | 2022-12-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $4.20 | +20.0K | 431.0K | +5% | +$84.0K |
| D | 2022-12-16 | 2022-12-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $15.88 | -20.0K | 411.0K | -5% | -$317.6K |
| 2022-11-17 | 2022-11-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $16.71 | -7,177 | 411.0K | -2% | -$119.9K | |
| 2022-08-05 | 2022-08-03 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | A - Grant | $0.00 | +28.9K | 425.3K | +7% | $0 | |
| 2022-08-05 | 2022-08-03 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $21.49 | -7,177 | 418.1K | -2% | -$154.2K | |
| 2022-05-17 | 2022-05-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $20.08 | -6,123 | 396.4K | -2% | -$122.9K | |
| 2022-03-08 | 2022-03-04 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | A - Grant | $0.00 | +59.5K | 402.5K | +17% | $0 | |
| M | 2022-02-17 | 2022-02-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $18.59 | -20.2K | 343.0K | -6% | -$375.1K |
| D | 2021-12-17 | 2021-12-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $17.44 | -47.5K | 363.2K | -12% | -$828.4K |
| D | 2021-12-17 | 2021-12-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $6.21 | +47.5K | 410.7K | +13% | +$295.0K |
| D | 2021-12-17 | 2021-12-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | A - Grant | $0.00 | +18.7K | 367.8K | +5% | $0 |
| D | 2021-12-17 | 2021-12-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $17.00 | -4,646 | 363.2K | -1% | -$79.0K |
| D | 2021-11-17 | 2021-11-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $18.09 | -47.5K | 411.2K | -10% | -$859.3K |
| DM | 2021-11-17 | 2021-11-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $18.10 | -62.2K | 404.4K | -13% | -$1.13M |
| D | 2021-11-17 | 2021-11-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $6.21 | +47.5K | 458.7K | +12% | +$295.0K |
| D | 2021-10-15 | 2021-10-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $6.21 | +47.5K | 458.7K | +12% | +$295.0K |
| D | 2021-10-15 | 2021-10-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $21.92 | -47.5K | 411.2K | -10% | -$1.04M |
| 2021-10-04 | 2021-09-30 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | A - Grant | $0.00 | +28.9K | 418.4K | +7% | $0 | |
| 2021-10-04 | 2021-09-30 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $20.63 | -7,177 | 411.2K | -2% | -$148.1K | |
| D | 2021-09-17 | 2021-09-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $6.21 | +47.5K | 437.0K | +12% | +$295.0K |
| D | 2021-09-17 | 2021-09-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $20.46 | -47.5K | 389.5K | -11% | -$971.9K |
| D | 2021-08-18 | 2021-08-16 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $18.44 | -55.0K | 389.5K | -12% | -$1.01M |
| D | 2021-08-18 | 2021-08-16 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $1.90 | +55.0K | 444.5K | +14% | +$104.5K |
| D | 2021-07-16 | 2021-07-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $17.47 | -60.0K | 389.5K | -13% | -$1.05M |
| D | 2021-07-16 | 2021-07-15 | EXEL | EXELIXIS, INC. | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $1.90 | +60.0K | 449.5K | +15% | +$114.0K |
Purchase Sale Sale after option exercise All abbreviations